organization · Reporting owner

Remeditex Ventures LLC

Disclosed activity across 4 companies

Tapewire entity: 132214
SEC CIK: 0001627363

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Apollo Endosurgery, Inc.APEN · Entity 114713	10% owner	December 29, 2016	December 30, 2016
Soliton, Inc.SOLY · Entity 132212	10% owner	December 16, 2021	December 17, 2021
Viridian Therapeutics, Inc.\DEMGEN · Entity 4316	10% owner	February 13, 2017	February 13, 2017
Yarrow Bioscience, Inc.MNLO · Entity 6871	10% owner	January 25, 2018	January 29, 2018

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Apollo Endosurgery, Inc.

Report date December 29, 2016 · Filed December 30, 2016

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,309,392	Reported balance After 2019-12-29 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2019-12-29 · Other · Acquired 1,309,392 · Balance 1,309,392 F1: Shares of common stock of the corporation then known as Apollo Endosurgery, Inc. ("Old Apollo") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of September 8, 2016, by and among the Issuer, Merger Sub, Inc. and Old Apollo (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into 0.3163 shares of the Issuer's common stock. Following the merger, the Issuer effected a reverse stock split at a ratio of one new share for every five and one half shares of common stock outstanding. F2: These securities are held directly by Remeditex Ventures, LLC. John W. Creecy is the Chief Executive Officer and Director of Remeditex Ventures, LLC and may be deemed to be the beneficial owner of the securities held by Remeditex Ventures, LLC. Mr. Creecy is a director of the Issuer and, accordingly, files separate Section 16 reports.

Filing footnotes · ownership attribution and instrument terms

F1: Shares of common stock of the corporation then known as Apollo Endosurgery, Inc. ("Old Apollo") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of September 8, 2016, by and among the Issuer, Merger Sub, Inc. and Old Apollo (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into 0.3163 shares of the Issuer's common stock. Following the merger, the Issuer effected a reverse stock split at a ratio of one new share for every five and one half shares of common stock outstanding.

F2: These securities are held directly by Remeditex Ventures, LLC. John W. Creecy is the Chief Executive Officer and Director of Remeditex Ventures, LLC and may be deemed to be the beneficial owner of the securities held by Remeditex Ventures, LLC. Mr. Creecy is a director of the Issuer and, accordingly, files separate Section 16 reports.

Soliton, Inc.

Report date December 16, 2021 · Filed December 17, 2021

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2021-12-16 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2021-12-16 · Disposition to issuer · Disposed 9,214,277 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of May 8, 2021 (the "Merger Agreement"), by and among Soliton, Inc. (the "Company"), AbbVie Inc. ("AbbVie") and Scout Merger Sub, Inc., a wholly owned subsidiary of AbbVie ("Merger Sub"), at the effective time of the merger of Merger Sub with and into the Company (the "Merger"), these shares of Company common stock were converted into the right to receive $22.60 in cash (the "Merger Consideration"), without interest. F2: Remeditex Ventures LLC is the record and beneficial owner of the shares of common stock and the warrant to purchase common stock subject to this Form 4 and shares voting and dispositive power over such securities with Malachite Trust, the majority owner of Remeditex Ventures LLC and Lyda Hill. Ms. Hill is the Trustee of the Malachite Trust. By reason of such relationships, Ms. Hill, the Malachite Trust and Remeditex Ventures LLC may be deemed to share voting and dispositive power over the securities owned directly by Remeditex Ventures LLC. Remeditex Ventures LLC, the Malachite Trust and Lyda Hill each disclaims beneficial ownership of the reported securities except to the extent of its or her pecuniary interest therein.
Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2024-06-19	Direct	Reported balance After 2021-12-16 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-12-16 · Disposition to issuer · Disposed 250,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the effective time of the Merger, each outstanding and unexercised warrant, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the excess of (i) the number of shares of common stock subject to the warrant, multiplied by the Merger Consideration over (ii) the number of shares of common stock subject to the warrant, multiplied by the per share exercise price of such warrant. F2: Remeditex Ventures LLC is the record and beneficial owner of the shares of common stock and the warrant to purchase common stock subject to this Form 4 and shares voting and dispositive power over such securities with Malachite Trust, the majority owner of Remeditex Ventures LLC and Lyda Hill. Ms. Hill is the Trustee of the Malachite Trust. By reason of such relationships, Ms. Hill, the Malachite Trust and Remeditex Ventures LLC may be deemed to share voting and dispositive power over the securities owned directly by Remeditex Ventures LLC. Remeditex Ventures LLC, the Malachite Trust and Lyda Hill each disclaims beneficial ownership of the reported securities except to the extent of its or her pecuniary interest therein.
Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.88 · Expires 2024-10-11	Direct	Reported balance After 2021-12-16 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-12-16 · Disposition to issuer · Disposed 170,808 · Balance 0 F3: Pursuant to the Merger Agreement, at the effective time of the Merger, each outstanding and unexercised warrant, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the excess of (i) the number of shares of common stock subject to the warrant, multiplied by the Merger Consideration over (ii) the number of shares of common stock subject to the warrant, multiplied by the per share exercise price of such warrant. F2: Remeditex Ventures LLC is the record and beneficial owner of the shares of common stock and the warrant to purchase common stock subject to this Form 4 and shares voting and dispositive power over such securities with Malachite Trust, the majority owner of Remeditex Ventures LLC and Lyda Hill. Ms. Hill is the Trustee of the Malachite Trust. By reason of such relationships, Ms. Hill, the Malachite Trust and Remeditex Ventures LLC may be deemed to share voting and dispositive power over the securities owned directly by Remeditex Ventures LLC. Remeditex Ventures LLC, the Malachite Trust and Lyda Hill each disclaims beneficial ownership of the reported securities except to the extent of its or her pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of May 8, 2021 (the "Merger Agreement"), by and among Soliton, Inc. (the "Company"), AbbVie Inc. ("AbbVie") and Scout Merger Sub, Inc., a wholly owned subsidiary of AbbVie ("Merger Sub"), at the effective time of the merger of Merger Sub with and into the Company (the "Merger"), these shares of Company common stock were converted into the right to receive $22.60 in cash (the "Merger Consideration"), without interest.

F2: Remeditex Ventures LLC is the record and beneficial owner of the shares of common stock and the warrant to purchase common stock subject to this Form 4 and shares voting and dispositive power over such securities with Malachite Trust, the majority owner of Remeditex Ventures LLC and Lyda Hill. Ms. Hill is the Trustee of the Malachite Trust. By reason of such relationships, Ms. Hill, the Malachite Trust and Remeditex Ventures LLC may be deemed to share voting and dispositive power over the securities owned directly by Remeditex Ventures LLC. Remeditex Ventures LLC, the Malachite Trust and Lyda Hill each disclaims beneficial ownership of the reported securities except to the extent of its or her pecuniary interest therein.

F3: Pursuant to the Merger Agreement, at the effective time of the Merger, each outstanding and unexercised warrant, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the excess of (i) the number of shares of common stock subject to the warrant, multiplied by the Merger Consideration over (ii) the number of shares of common stock subject to the warrant, multiplied by the per share exercise price of such warrant.

Viridian Therapeutics, Inc.\DE

Report date February 13, 2017 · Filed February 13, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,706,563	Reported balance Holding disclosure · report date 2017-02-13 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 2,706,563 F1: Shares of common stock of the corporation then known as Miragen Therapeutics, Inc. ("Old Miragen") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of October 31, 2016, by and among the Issuer, Signal Merger Sub, Inc. and Old Miragen (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into 0.7031 shares of the Issuer's common stock. F2: Represents 3,849,471 shares of common stock of Old Miragen prior to conversion pursuant to the Merger Agreement including: 797,308 shares of common stock of Old Miragen; and shares of common stock of Old Miragen issued upon the conversion of 1,083,333 shares of Series B preferred stock of Old Miragen and 1,968,830 shares of Series C preferred stock of Old Miragen. Immediately prior to the effective time of the merger, each share of Old Miragen preferred stock converted into one share of Old Miragen's common stock.

Filing footnotes · ownership attribution and instrument terms

F1: Shares of common stock of the corporation then known as Miragen Therapeutics, Inc. ("Old Miragen") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of October 31, 2016, by and among the Issuer, Signal Merger Sub, Inc. and Old Miragen (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into 0.7031 shares of the Issuer's common stock.

F2: Represents 3,849,471 shares of common stock of Old Miragen prior to conversion pursuant to the Merger Agreement including: 797,308 shares of common stock of Old Miragen; and shares of common stock of Old Miragen issued upon the conversion of 1,083,333 shares of Series B preferred stock of Old Miragen and 1,968,830 shares of Series C preferred stock of Old Miragen. Immediately prior to the effective time of the merger, each share of Old Miragen preferred stock converted into one share of Old Miragen's common stock.

Yarrow Bioscience, Inc.

Report date January 25, 2018 · Filed January 29, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,761,663	Ending reported balance After 2018-01-29 transaction · row 4 4 source rows · reconciled sequence Row 1 · 2018-01-25 · Purchase · Acquired 100,000 · Balance 1,582,854 Row 2 · 2018-01-29 · Conversion · Acquired 2,650 · Balance 1,585,504 F1: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock. Row 3 · 2018-01-29 · Conversion · Acquired 871,583 · Balance 2,457,087 F1: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock. Row 4 · 2018-01-29 · Conversion · Acquired 304,576 · Balance 2,761,663 F1: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock.
Series A Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-01-29 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2018-01-29 · Conversion · Disposed 7,150 · Balance 0 F1: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock.
Series B Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-01-29 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2018-01-29 · Conversion · Disposed 2,351,097 · Balance 0 F1: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock.
Series C Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-01-29 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2018-01-29 · Conversion · Disposed 821,596 · Balance 0 F1: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock.

Filing footnotes · ownership attribution and instrument terms

F1: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
December 16, 2021 Filed Dec 17, 2021 17:09 UTC	Soliton, Inc. SOLY · Entity 132212	Disposition to issuerWarrant (right to buy) · Derivative	170,808	Not disclosed Strike: $12.88	Not disclosed	Disclosure SEC source: 0001548187-21-000080 · wf-form4_163977897775621.xml · derivative · entry 3 Remeditex Ventures LLC · CIK 0001627363 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 170,808 shares Expires 2024-10-11 F3 · price: Pursuant to the Merger Agreement, at the effective time of the Merger, each outstanding and unexercised warrant, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the excess of (i) the number of shares of common stock subject to the warrant, multiplied by the Merger Consideration over (ii) the number of shares of common stock subject to the warrant, multiplied by the per share exercise price of such warrant. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger, each outstanding and unexercised warrant, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the excess of (i) the number of shares of common stock subject to the warrant, multiplied by the Merger Consideration over (ii) the number of shares of common stock subject to the warrant, multiplied by the per share exercise price of such warrant. F2 · ownership.direct: Remeditex Ventures LLC is the record and beneficial owner of the shares of common stock and the warrant to purchase common stock subject to this Form 4 and shares voting and dispositive power over such securities with Malachite Trust, the majority owner of Remeditex Ventures LLC and Lyda Hill. Ms. Hill is the Trustee of the Malachite Trust. By reason of such relationships, Ms. Hill, the Malachite Trust and Remeditex Ventures LLC may be deemed to share voting and dispositive power over the securities owned directly by Remeditex Ventures LLC. Remeditex Ventures LLC, the Malachite Trust and Lyda Hill each disclaims beneficial ownership of the reported securities except to the extent of its or her pecuniary interest therein. Read SEC document
December 16, 2021 Filed Dec 17, 2021 17:09 UTC	Soliton, Inc. SOLY · Entity 132212	Disposition to issuerWarrant (right to buy) · Derivative	250,000	Not disclosed Strike: $16.00	Not disclosed	Disclosure SEC source: 0001548187-21-000080 · wf-form4_163977897775621.xml · derivative · entry 2 Remeditex Ventures LLC · CIK 0001627363 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250,000 shares Expires 2024-06-19 F3 · price: Pursuant to the Merger Agreement, at the effective time of the Merger, each outstanding and unexercised warrant, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the excess of (i) the number of shares of common stock subject to the warrant, multiplied by the Merger Consideration over (ii) the number of shares of common stock subject to the warrant, multiplied by the per share exercise price of such warrant. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger, each outstanding and unexercised warrant, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the excess of (i) the number of shares of common stock subject to the warrant, multiplied by the Merger Consideration over (ii) the number of shares of common stock subject to the warrant, multiplied by the per share exercise price of such warrant. F2 · ownership.direct: Remeditex Ventures LLC is the record and beneficial owner of the shares of common stock and the warrant to purchase common stock subject to this Form 4 and shares voting and dispositive power over such securities with Malachite Trust, the majority owner of Remeditex Ventures LLC and Lyda Hill. Ms. Hill is the Trustee of the Malachite Trust. By reason of such relationships, Ms. Hill, the Malachite Trust and Remeditex Ventures LLC may be deemed to share voting and dispositive power over the securities owned directly by Remeditex Ventures LLC. Remeditex Ventures LLC, the Malachite Trust and Lyda Hill each disclaims beneficial ownership of the reported securities except to the extent of its or her pecuniary interest therein. Read SEC document
December 16, 2021 Filed Dec 17, 2021 17:09 UTC	Soliton, Inc. SOLY · Entity 132212	Disposition to issuerCommon Stock	9,214,277	$22.60	$208,242,660.20	Disclosure SEC source: 0001548187-21-000080 · wf-form4_163977897775621.xml · nonDerivative · entry 1 Remeditex Ventures LLC · CIK 0001627363 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of May 8, 2021 (the "Merger Agreement"), by and among Soliton, Inc. (the "Company"), AbbVie Inc. ("AbbVie") and Scout Merger Sub, Inc., a wholly owned subsidiary of AbbVie ("Merger Sub"), at the effective time of the merger of Merger Sub with and into the Company (the "Merger"), these shares of Company common stock were converted into the right to receive $22.60 in cash (the "Merger Consideration"), without interest. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of May 8, 2021 (the "Merger Agreement"), by and among Soliton, Inc. (the "Company"), AbbVie Inc. ("AbbVie") and Scout Merger Sub, Inc., a wholly owned subsidiary of AbbVie ("Merger Sub"), at the effective time of the merger of Merger Sub with and into the Company (the "Merger"), these shares of Company common stock were converted into the right to receive $22.60 in cash (the "Merger Consideration"), without interest. F2 · ownership.direct: Remeditex Ventures LLC is the record and beneficial owner of the shares of common stock and the warrant to purchase common stock subject to this Form 4 and shares voting and dispositive power over such securities with Malachite Trust, the majority owner of Remeditex Ventures LLC and Lyda Hill. Ms. Hill is the Trustee of the Malachite Trust. By reason of such relationships, Ms. Hill, the Malachite Trust and Remeditex Ventures LLC may be deemed to share voting and dispositive power over the securities owned directly by Remeditex Ventures LLC. Remeditex Ventures LLC, the Malachite Trust and Lyda Hill each disclaims beneficial ownership of the reported securities except to the extent of its or her pecuniary interest therein. Read SEC document
June 30, 2020 Filed Jul 1, 2020 20:30 UTC	Soliton, Inc. SOLY · Entity 132212	PurchaseCommon Stock	120,481	$8.30	$999,992.30	Disclosure SEC source: 0001548187-20-000086 · wf-form4_159364983717876.xml · nonDerivative · entry 1 Remeditex Ventures LLC · CIK 0001627363 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,214,277 F1 · ownership.direct: Remeditex Ventures LLC is the record and beneficial owner of the shares of common stock subject to this Form 4 and shares voting and dispositive power over such securities with Malachite Trust, the majority owner of Remeditex Ventures LLC and Lyda Hill. Ms. Hill is the Trustee of the Malachite Trust. By reason of such relationships, Ms. Hill, the Malachite Trust and Remeditex Ventures LLC may be deemed to share voting and dispositive power over the securities owned directly by Remeditex Ventures LLC. Remeditex Ventures LLC, the Malachite Trust and Lyda Hill each disclaims beneficial ownership of the reported securities except to the extent of its or her pecuniary interest therein. Read SEC document
December 29, 2019 Filed Dec 30, 2016 08:31 UTC	Apollo Endosurgery, Inc. APEN · Entity 114713	OtherCommon Stock	1,309,392	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-16-033598 · edgar.xml · nonDerivative · entry 1 Remeditex Ventures LLC · CIK 0001627363 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,309,392 F1 · kind: Shares of common stock of the corporation then known as Apollo Endosurgery, Inc. ("Old Apollo") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of September 8, 2016, by and among the Issuer, Merger Sub, Inc. and Old Apollo (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into 0.3163 shares of the Issuer's common stock. Following the merger, the Issuer effected a reverse stock split at a ratio of one new share for every five and one half shares of common stock outstanding. F1 · price: Shares of common stock of the corporation then known as Apollo Endosurgery, Inc. ("Old Apollo") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of September 8, 2016, by and among the Issuer, Merger Sub, Inc. and Old Apollo (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into 0.3163 shares of the Issuer's common stock. Following the merger, the Issuer effected a reverse stock split at a ratio of one new share for every five and one half shares of common stock outstanding. F2 · ownership.direct: These securities are held directly by Remeditex Ventures, LLC. John W. Creecy is the Chief Executive Officer and Director of Remeditex Ventures, LLC and may be deemed to be the beneficial owner of the securities held by Remeditex Ventures, LLC. Mr. Creecy is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document
October 11, 2019 Filed Oct 15, 2019 18:08 UTC	Soliton, Inc. SOLY · Entity 132212	PurchaseWarrant (right to buy) · Derivative	170,808	Not disclosed Strike: $12.88	Not disclosed	Disclosure SEC source: 0001437749-19-020084 · rdgdoc.xml · derivative · entry 2 Remeditex Ventures LLC · CIK 0001627363 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 420,808 Underlying: Common Stock · 170,808 shares Expires 2024-10-11 F1 · price: The common stock and warrant was issued as part of a unit of securities consisting of (i) one share of the Issuer's common stock, and (ii) 1.1 of a warrant to purchase one share of common stock. The offering price of the units was $12.88 per unit. F2 · ownership.direct: Remeditex Ventures LLC is the record and beneficial owner of the shares of common stock and the warrant to purchase common stock subject to this Form 4 and shares voting and dispositive power over such securities with Malachite Trust, the majority owner of Remeditex Ventures LLC and Lyda Hill. Ms. Hill is the Trustee of the Malachite Trust. By reason of such relationships, Ms. Hill, the Malachite Trust and Remeditex Ventures LLC may be deemed to share voting and dispositive power over the securities owned directly by Remeditex Ventures LLC. Remeditex Ventures LLC, the Malachite Trust and Lyda Hill each disclaims beneficial ownership of the reported securities except to the extent of its or her pecuniary interest therein. Read SEC document
October 11, 2019 Filed Oct 15, 2019 18:08 UTC	Soliton, Inc. SOLY · Entity 132212	PurchaseCommon Stock	155,280	Not disclosed	Not disclosed	Disclosure SEC source: 0001437749-19-020084 · rdgdoc.xml · nonDerivative · entry 1 Remeditex Ventures LLC · CIK 0001627363 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,093,796 F1 · price: The common stock and warrant was issued as part of a unit of securities consisting of (i) one share of the Issuer's common stock, and (ii) 1.1 of a warrant to purchase one share of common stock. The offering price of the units was $12.88 per unit. F2 · ownership.direct: Remeditex Ventures LLC is the record and beneficial owner of the shares of common stock and the warrant to purchase common stock subject to this Form 4 and shares voting and dispositive power over such securities with Malachite Trust, the majority owner of Remeditex Ventures LLC and Lyda Hill. Ms. Hill is the Trustee of the Malachite Trust. By reason of such relationships, Ms. Hill, the Malachite Trust and Remeditex Ventures LLC may be deemed to share voting and dispositive power over the securities owned directly by Remeditex Ventures LLC. Remeditex Ventures LLC, the Malachite Trust and Lyda Hill each disclaims beneficial ownership of the reported securities except to the extent of its or her pecuniary interest therein. Read SEC document
June 19, 2019 Filed Jun 19, 2019 17:16 UTC	Soliton, Inc. SOLY · Entity 132212	PurchaseWarrant (right to buy) · Derivative	250,000	Not disclosed Strike: $16.00	Not disclosed	Disclosure SEC source: 0001437749-19-012300 · rdgdoc.xml · derivative · entry 2 Remeditex Ventures LLC · CIK 0001627363 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires not disclosed F1 · price: The common stock and warrant was issued as part of a unit of securities consisting of (i) one share of the Issuer's common stock, and (ii) 0.7 of a warrant to purchase one share of common stock. The offering price of the units was $14.00 per unit. F3 · derivative.expiration_date: The warrant expires five years after the effective date of the resale registration statement registering the shares of common stock underlying the warrant, or when such shares may sold without restriction pursuant to Rule 144 of the Securities Act of 1933. F2 · ownership.direct: Remeditex Ventures LLC is the record and beneficial owner of the shares of common stock and the warrant to purchase common stock subject to this Form 4 and shares voting and dispositive power over such securities with Malachite Trust, the majority owner of Remeditex Ventures LLC and Lyda Hill. Ms. Hill is the Trustee of the Malachite Trust. By reason of such relationships, Ms. Hill, the Malachite Trust and Remeditex Ventures LLC may be deemed to share voting and dispositive power over the securities owned directly by Remeditex Ventures LLC. Remeditex Ventures LLC, the Malachite Trust and Lyda Hill each disclaims beneficial ownership of the reported securities except to the extent of its or her pecuniary interest therein. Read SEC document
June 19, 2019 Filed Jun 19, 2019 17:16 UTC	Soliton, Inc. SOLY · Entity 132212	PurchaseCommon Stock	357,143	Not disclosed	Not disclosed	Disclosure SEC source: 0001437749-19-012300 · rdgdoc.xml · nonDerivative · entry 1 Remeditex Ventures LLC · CIK 0001627363 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,938,516 F1 · price: The common stock and warrant was issued as part of a unit of securities consisting of (i) one share of the Issuer's common stock, and (ii) 0.7 of a warrant to purchase one share of common stock. The offering price of the units was $14.00 per unit. F2 · ownership.direct: Remeditex Ventures LLC is the record and beneficial owner of the shares of common stock and the warrant to purchase common stock subject to this Form 4 and shares voting and dispositive power over such securities with Malachite Trust, the majority owner of Remeditex Ventures LLC and Lyda Hill. Ms. Hill is the Trustee of the Malachite Trust. By reason of such relationships, Ms. Hill, the Malachite Trust and Remeditex Ventures LLC may be deemed to share voting and dispositive power over the securities owned directly by Remeditex Ventures LLC. Remeditex Ventures LLC, the Malachite Trust and Lyda Hill each disclaims beneficial ownership of the reported securities except to the extent of its or her pecuniary interest therein. Read SEC document
January 29, 2018 Filed Jan 29, 2018 21:19 UTC	Yarrow Bioscience, Inc. MNLO · Entity 6871	ConversionSeries C Preferred Stock · Derivative	821,596	$0.00	$0.00	Disclosure SEC source: 0001209191-18-005831 · doc4.xml · derivative · entry 7 Remeditex Ventures LLC · CIK 0001627363 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 304,576 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock. F1 · price: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock. F1 · derivative.exercise_date: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock. F1 · derivative.expiration_date: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock. Read SEC document
January 29, 2018 Filed Jan 29, 2018 21:19 UTC	Yarrow Bioscience, Inc. MNLO · Entity 6871	ConversionSeries B Preferred Stock · Derivative	2,351,097	$0.00	$0.00	Disclosure SEC source: 0001209191-18-005831 · doc4.xml · derivative · entry 6 Remeditex Ventures LLC · CIK 0001627363 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 871,583 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock. F1 · price: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock. F1 · derivative.exercise_date: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock. F1 · derivative.expiration_date: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock. Read SEC document
January 29, 2018 Filed Jan 29, 2018 21:19 UTC	Yarrow Bioscience, Inc. MNLO · Entity 6871	ConversionSeries A Preferred Stock · Derivative	7,150	$0.00	$0.00	Disclosure SEC source: 0001209191-18-005831 · doc4.xml · derivative · entry 5 Remeditex Ventures LLC · CIK 0001627363 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,650 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock. F1 · price: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock. F1 · derivative.exercise_date: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock. F1 · derivative.expiration_date: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock. Read SEC document
January 29, 2018 Filed Jan 29, 2018 21:19 UTC	Yarrow Bioscience, Inc. MNLO · Entity 6871	ConversionCommon Stock	304,576	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-005831 · doc4.xml · nonDerivative · entry 4 Remeditex Ventures LLC · CIK 0001627363 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,761,663 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock. Read SEC document
January 29, 2018 Filed Jan 29, 2018 21:19 UTC	Yarrow Bioscience, Inc. MNLO · Entity 6871	ConversionCommon Stock	871,583	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-005831 · doc4.xml · nonDerivative · entry 3 Remeditex Ventures LLC · CIK 0001627363 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,457,087 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock. Read SEC document
January 29, 2018 Filed Jan 29, 2018 21:19 UTC	Yarrow Bioscience, Inc. MNLO · Entity 6871	ConversionCommon Stock	2,650	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-005831 · doc4.xml · nonDerivative · entry 2 Remeditex Ventures LLC · CIK 0001627363 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,585,504 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock. Read SEC document
January 25, 2018 Filed Jan 29, 2018 21:19 UTC	Yarrow Bioscience, Inc. MNLO · Entity 6871	PurchaseCommon Stock	100,000	$17.00	$1,700,000.00	Disclosure SEC source: 0001209191-18-005831 · doc4.xml · nonDerivative · entry 1 Remeditex Ventures LLC · CIK 0001627363 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,582,854 Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.